As previously reported, William Blair analyst Andy Hsieh upgraded Terns Pharmaceuticals (TERN) to Outperform from Market Perform after the company announced data from the ongoing CARDINAL trial of TERN-701 in participants with previously treated chronic myeloid leukemia. The overall major molecular response rate of 75%, with 64% achieving MMR by 24 weeks, is “impressive” and “topples investors expectations” and the competitive bar, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals upgraded to Outperform from Market Perform at William Blair
- Terns Pharmaceuticals Announces CARDINAL Trial Data Presentation
- Terns Pharmaceuticals announces data from CARDINAL trial of TERN-701
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Terns Pharmaceuticals price target lowered to $15 from $20 at Citizens JMP